Skip to main content
Colour image of nerves in the brain


Developing new ways to detect and treat neurological disease

Our neuroimmunology team focuses on improving our understanding of neurological and psychiatric diseases. It has become clear that many of these diseases are associated with a dysregulation of the immune system.

Autoantibodies are one arm of the immune system and are important in many childhood and adult nervous system disorders. In fact, they define certain clinical syndromes. This provides us with unprecedented opportunity to develop novel diagnostic biomarkers of disease. Most importantly, we are developing new and innovative treatments for some of the most debilitating neurological diseases.

Our collective expertise in detecting autoantibodies and other biomarkers, exploring antibody pathogenicity, neuropathology, imaging and clinical service delivery puts us at the forefront of this research.

Our focus is on identifying and investigating immune-mediated and antibody-mediated neurological diseases, such as:

  • demyelinating diseases such as multiple sclerosis
  • motor neurone disease
  • psychiatric diseases
  • movement disorders
  • dementia
  • myasthenia gravis, and more.

In so doing, we can develop new and more effective ways of diagnosing these conditions. Further, our improved understanding of the effects of autoantibodies in these disorders enables us to focus on developing new and innovative treatments.

Integrating our basic laboratory research, clinically applied research and health service provision will enable us to translate our findings into real-world applications.

This research program stems from our collaboration with academics and clinicians from Westmead Hospital, the Children’s Hospital at Westmead, Westmead Institute for Medical Research, Save Sight Institute, Bosch Institute, Royal Prince Alfred Hospital and Concord Hospital.